MarketBeat published analyst ratings regarding the business of ICU Medical and High Tide.
1 report, 1 independent
Updated Jun 29
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat published analyst ratings regarding the business of ICU Medical and High Tide.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
MarketBeat
American personal finance blog
- Jefferies Financial Group began coverage, Morgan Stanley set a high price target, and Keefe, Bruyette & Woods increased price objectives, with MarketBeat reporting the average stock rating.
- Scotiabank raised its price target and Bank of America upgraded its rating on May 27, 2026, with MarketBeat aggregating the data.
-
ICU Medical
California-based company that develops, manufactures, and sells medical technologies used in vascular therapy, oncology, and critical care applications
Nothing else this week.
Related events
- MarketBeat provided analyst recommendations and compared Organon & Co. and Xeris Biopharma.
- MarketBeat reports on company ratings and targets for Nikon Corporation and Jabil, comparing business profiles and financial health.
- MarketBeat reported analyst recommendations for Cytokinetics and Gain Therapeutics, two competing healthcare companies.
- MarketBeat provided analyst ratings for technology companies Plexus and Cemtrex.
- MarketBeat provided analyst ratings for CPS Technologies Corp. on October 22, 2026.